-
公开(公告)号:US08927694B2
公开(公告)日:2015-01-06
申请号:US13130007
申请日:2009-10-14
IPC分类号: C07K16/00 , C07K14/765 , A61K38/00
CPC分类号: C07K16/32 , A61K38/00 , A61K2039/505 , C07K14/765 , C07K16/2863 , C07K16/40 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2317/94 , C07K2319/31 , C07K2319/74
摘要: Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate.
摘要翻译: 披露了与其结合的结合,诊断和治疗剂的人血清白蛋白(HSA)接头和HSA接头。 还公开了缀合物,其中HSA接头共价键合到作为第一和第二单链Fv分子(scFv)的氨基和羧基末端结合部分。 示例性缀合物可用于例如减少肿瘤细胞增殖,例如用于治疗性治疗应用。 还公开了用于诊断和治疗应用HSA接头缀合物的方法和试剂盒。
-
公开(公告)号:US20120003221A1
公开(公告)日:2012-01-05
申请号:US13130007
申请日:2009-10-14
IPC分类号: A61K39/395 , A61P35/00 , C07K19/00
CPC分类号: C07K16/32 , A61K38/00 , A61K2039/505 , C07K14/765 , C07K16/2863 , C07K16/40 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2317/94 , C07K2319/31 , C07K2319/74
摘要: Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate.
摘要翻译: 披露了与其结合的结合,诊断和治疗剂的人血清白蛋白(HSA)接头和HSA接头。 还公开了缀合物,其中HSA接头共价键合到作为第一和第二单链Fv分子(scFv)的氨基和羧基末端结合部分。 示例性缀合物可用于例如减少肿瘤细胞增殖,例如用于治疗性治疗应用。 还公开了用于诊断和治疗应用HSA接头缀合物的方法和试剂盒。
-
公开(公告)号:US20110059076A1
公开(公告)日:2011-03-10
申请号:US12757801
申请日:2010-04-09
IPC分类号: A61K39/395 , C07K14/765 , A61K31/517 , A61K31/337 , A61K31/4196 , A61K38/00 , A61K31/4375 , A61K33/24 , A61K31/282 , A61K31/138 , A61K31/519 , A61K31/513 , A61K31/704 , A61P35/00
CPC分类号: C07K16/32 , A61K38/00 , A61K2039/505 , C07K14/765 , C07K16/2863 , C07K16/40 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2317/94 , C07K2319/31 , C07K2319/74
摘要: Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate.
摘要翻译: 披露了与其结合的结合,诊断和治疗剂的人血清白蛋白(HSA)接头和HSA接头。 还公开了缀合物,其中HSA接头共价键合到作为第一和第二单链Fv分子(scFv)的氨基和羧基末端结合部分。 示例性缀合物可用于例如减少肿瘤细胞增殖,例如用于治疗性治疗应用。 还公开了用于诊断和治疗应用HSA接头缀合物的方法和试剂盒。
-
公开(公告)号:US20140056898A1
公开(公告)日:2014-02-27
申请号:US14001448
申请日:2012-02-24
申请人: Bo Zhang , Charlotte McDonagh , Alexandra Huhalov
发明人: Bo Zhang , Charlotte McDonagh , Alexandra Huhalov
IPC分类号: A61K39/395 , A61K31/138 , A61K31/4196 , A61K31/337 , A61K31/517 , A61K31/7068 , A61K33/24 , A61K31/565 , A61K45/06
CPC分类号: A61K39/3955 , A61K31/138 , A61K31/337 , A61K31/4196 , A61K31/517 , A61K31/565 , A61K31/7068 , A61K33/24 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/32 , C07K2317/622 , C07K2317/73 , C07K2319/31 , A61K2300/00
摘要: Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering either i) an effective amount of an anti-estrogen agent or ii) an effective amount of a receptor tyrosine kinase inhibitor and an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody, and optionally an effective amount trastuzumab. Also disclosed is a bispecific anti-ErbB2/anti-ErbB3 antibody for use in the therapy of a tumor in combination with either i) an anti-estrogen agent or ii) a receptor tyrosine kinase inhibitor, and optionally in use with trastuzumab.
摘要翻译: 公开了用于抑制受试者中肿瘤(例如恶性肿瘤)生长的方法和组合物。 特别地,用于通过共同施用i)有效量的抗雌激素剂或ii)有效量的受体酪氨酸激酶抑制剂和有效量的双特异性抗ErbB2来治疗受试者中的肿瘤的组合疗法 /抗ErbB3抗体,以及任选的有效量的曲妥珠单抗。 还公开了用于治疗肿瘤的双特异性抗ErbB2 /抗ErbB3抗体,其与i)抗雌激素剂或ii)受体酪氨酸激酶抑制剂组合,并且任选地与曲妥单抗一起使用。
-
公开(公告)号:US20110312088A1
公开(公告)日:2011-12-22
申请号:US13109957
申请日:2011-05-17
申请人: Charlotte McDonagh , Charles G. Cerveny , Dennis Benjamin , Paul Carter , Hans Peter Gerber , Leigh Francisco
发明人: Charlotte McDonagh , Charles G. Cerveny , Dennis Benjamin , Paul Carter , Hans Peter Gerber , Leigh Francisco
CPC分类号: A61K47/6803 , A61K38/05 , A61K47/6811 , A61K47/6849 , A61K47/6867 , A61K2039/505 , C07K16/2803 , C07K16/3061 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/77 , Y02A50/401 , Y02A50/41 , Y02A50/412 , Y02A50/414 , Y02A50/423
摘要: This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
摘要翻译: 本发明尤其涉及CD19结合剂和使用这种CD19结合剂来治疗疾病的方法。
-
公开(公告)号:US07968687B2
公开(公告)日:2011-06-28
申请号:US12253895
申请日:2008-10-17
IPC分类号: C12P21/08
CPC分类号: A61K47/6803 , A61K38/05 , A61K47/6811 , A61K47/6849 , A61K47/6867 , A61K2039/505 , C07K16/2803 , C07K16/3061 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/77 , Y02A50/401 , Y02A50/41 , Y02A50/412 , Y02A50/414 , Y02A50/423
摘要: This invention relates to CD 19 binding agents and methods of using such CD 19 binding agents for treating disease.
摘要翻译: 本发明涉及CD19结合剂和使用这种CD19结合剂治疗疾病的方法。
-
公开(公告)号:US20100158909A1
公开(公告)日:2010-06-24
申请号:US12516914
申请日:2007-12-01
申请人: Charlotte McDonagh , Paul Carter , Django Sussman
发明人: Charlotte McDonagh , Paul Carter , Django Sussman
IPC分类号: A61K39/395 , C07K16/00 , A61P37/06
CPC分类号: A61K47/48561 , A61K47/6811 , A61K47/6849 , A61K47/6861 , A61K51/1027 , A61K2039/505 , C07K16/2875 , C07K16/30 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/732 , C07K2317/734 , C07K2317/92
摘要: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
摘要翻译: 本发明提供了与使用这种结合剂预防或治疗癌症和免疫学疾病有关的变体靶结合剂和方法。 变体靶结合剂与对靶细胞发挥细胞毒性,细胞抑制或免疫调节作用的治疗剂缀合。
-
公开(公告)号:US08455622B2
公开(公告)日:2013-06-04
申请号:US12516914
申请日:2007-12-01
申请人: Charlotte McDonagh , Paul Carter , Django Sussman
发明人: Charlotte McDonagh , Paul Carter , Django Sussman
CPC分类号: A61K47/48561 , A61K47/6811 , A61K47/6849 , A61K47/6861 , A61K51/1027 , A61K2039/505 , C07K16/2875 , C07K16/30 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/732 , C07K2317/734 , C07K2317/92
摘要: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
-
公开(公告)号:US08067546B2
公开(公告)日:2011-11-29
申请号:US11912096
申请日:2006-04-19
CPC分类号: C07K16/2875 , A61K2039/505 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2317/92 , Y02A50/386
摘要: Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.
摘要翻译: 公开了CD70结合剂,例如在表达CD70的细胞上发挥细胞毒性,细胞抑制或免疫调节的人源化抗CD70抗体和片段和衍生物,以及包含抗体,片段或衍生物的药物组合物和试剂盒。 还公开了用于治疗表达CD70的癌症和免疫学疾病的方法,其包括对受试者施用CD70结合剂或药物组合物。
-
公开(公告)号:US20100239571A1
公开(公告)日:2010-09-23
申请号:US12438604
申请日:2007-08-24
申请人: Charlotte McDonagh , Paul Carter
发明人: Charlotte McDonagh , Paul Carter
CPC分类号: C07K16/2878 , A61K47/6811 , A61K47/6849 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要: This invention relates to CD30 binding agents and methods of using such binding agents for treating disease characterized by expression of CD30 antigen.
摘要翻译: 本发明涉及CD30结合剂和使用这种结合剂治疗特征在于表达CD30抗原的疾病的方法。
-
-
-
-
-
-
-
-
-